Future of Radiotherapy in Nasopharyngeal Carcinoma
- 9 July 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 92 (1102) , 20190209
Abstract
Nasopharyngeal carcinoma (NPC) is a malignancy with unique clinical biological profiles such as associated Epstein-Barr virus infection and high radiosensitivity. Radiotherapy has long been recognized as the mainstay for the treatment of NPC. However, the further efficacy brought by radical radiotherapy has reached the bottleneck in advanced patients, who are prone to develop recurrence and distant metastasis after treatment. The application of photon therapy makes it possible for radiation dose escalation in refractory cases and may provide second chance for recurrent patients with less unrecoverable tissue damage. The concept of adaptive radiotherapy is put forward in consideration of target volume shrinkage during treatment. The replanning procedure offers better protection for the organ at risk. However, the best timing and candidates for adaptive radiotherapy is still under debate. The current tendency of artificial intelligence in NPC mainly focuses on image recognition, auto-segmentation and dose prediction. Although artificial intelligence is still in developmental stage, the future of it is promising. To further improve the efficacy of NPC, multimodality treatment is encouraged. In-depth studies on genetic and epigenetic variations help to explain the great heterogeneity among patients, and could further be applied to precise screening and prediction, personalized radiotherapy and the evolution of targeted drugs. Given the clinical benefit of immunotherapy in other cancers, the application of immunotherapy, especially immune checkpoint inhibitor, in NPC is also of great potential. Results from ongoing clinical trials combining immunotherapy with radiotherapy in NPC are expected.Keywords
This publication has 79 references indexed in Scilit:
- Identification of a recurrent transforming UBR5–ZNF423 fusion gene in EBV‐associated nasopharyngeal carcinomaThe Journal of Pathology, 2013
- Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients With Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Adaptive radiotherapy for head and neck cancer—Dosimetric results from a prospective clinical trialRadiotherapy and Oncology, 2013
- Adaptive Planning in Intensity-Modulated Radiation Therapy for Head and Neck Cancers: Single-Institution Experience and Clinical ImplicationsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Intensity‐modulated radiation therapy reduces radiation‐induced trismus in patients with nasopharyngeal carcinomaCancer, 2011
- Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinomaChinese Journal of Cancer, 2009
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protonsRadiation Oncology, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004